Compare BWMX & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWMX | NGNE |
|---|---|---|
| Founded | 1995 | 2003 |
| Country | Mexico | United States |
| Employees | 2441 | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 621.6M | 744.9M |
| IPO Year | 2019 | 2014 |
| Metric | BWMX | NGNE |
|---|---|---|
| Price | $16.60 | $30.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $27.83 | ★ $63.57 |
| AVG Volume (30 Days) | 71.7K | ★ 234.1K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 9.11% | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.17 | N/A |
| Revenue Next Year | $25.68 | N/A |
| P/E Ratio | $12.54 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.34 | $15.93 |
| 52 Week High | $19.79 | $43.66 |
| Indicator | BWMX | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 41.25 |
| Support Level | N/A | $31.20 |
| Resistance Level | N/A | $33.99 |
| Average True Range (ATR) | 0.00 | 1.95 |
| MACD | 0.00 | -0.47 |
| Stochastic Oscillator | 0.00 | 20.29 |
Betterware de Mexico SAPI de CV is a company in the consumer product goods industry focused on home organization and beauty and personal care products, commercialized through person-to-person selling. The Group operates through two segments: Home organization under the Betterware brand, including kitchen and food preservation, home solutions, bathroom, laundry & cleaning, tech and mobility, bedroom and wellness. Products are sold through catalogues and distributed through distributors and associates. The Beauty and personal care (B&PC) segment under the JAFRA brand, which generates maximum revenue, includes fragrance, color, skin care and toiletries, distributed through leaders and consultants. The Group operates in Mexico, which generates maximum revenue, the United States and Latam.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.